Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 0.50 |
| ▸ | RXRA | P19793 | 2/20 | 0.47 |
| ▸ | RXRG | P48443 | 2/20 | 0.47 |
| ▸ | RXRB | P28702 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.44 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.38 |
| ▸ | MAOB | P27338 | 2/20 | 0.38 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16961681 | 0.86 | CES2 (0.44) | CES2RXRARXRGGPBAR1TAS2R14 | |
| SCHEMBL545065 | 0.84 | MRGPRX4 (0.57) | CES2RXRARXRGRXRBGPBAR1 | |
| SCHEMBL29488327 | 0.84 | MRGPRX4 (0.57) | CES2RXRARXRGRXRBGPBAR1 | |
| SCHEMBL12187783 | 0.84 | ALDH1A1 (0.42) | RXRARXRGRXRBALDH1A1MAPT | |
| SCHEMBL4283632 | 0.83 | CES2 (0.50) | CES2RXRARXRGGPBAR1TAS2R14 | |
| SCHEMBL2789789 | 0.83 | CES2 (0.50) | CES2RXRARXRGGPBAR1TAS2R14 | |
| SCHEMBL29656570 | 0.82 | RXRA (0.47) | CES2RXRARXRGGPBAR1TAS2R14 | |
| SCHEMBL28798652 | 0.82 | RXRA (0.47) | CES2RXRARXRGGPBAR1TAS2R14 | |
| SCHEMBL545041 | 0.82 | NOTUM (0.60) | CES2RXRARXRGGPBAR1TAS2R14 | |
| SCHEMBL13790659 | 0.81 | ALDH1A1 (0.52) | ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2149563-B9 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2149563-B1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | KOWA CO (JP) | 2015-01-07 | — | — | EP | disclosed |
| CN-101679363-B | Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same | KOWA CO | 2013-06-05 | — | — | CN | disclosed |
| EP-2138489-B9 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | KOWA CO (JP) | 2012-10-24 | — | — | EP | disclosed |
| EP-2138489-B1 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | KOWA CO (JP) | 2012-07-11 | — | — | EP | disclosed |
| CN-101679309-B | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2012-02-29 | — | — | CN | disclosed |
| US-8012989-B2 | Substituted pyrimidine compounds and their utility as CETP inhibitors | KOWA COMPANY, LTD. (JP) | 2011-09-06 | — | — | US | disclosed |
| US-20100249148-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | KOWA COMPANY, LTD. (JP) | 2010-09-30 | — | — | US | disclosed |
| US-7790737-B2 | Substituted pyrimidine compounds and their utility as CETP inhibitors | KOWA COMPANY, LTD. (JP) | 2010-09-07 | — | — | US | disclosed |
| CN-101679309-A | Novel pyrimidine compound having dibenzylamine structure, and medicine comprising the compound | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| CN-101679363-A | Novel pyrimidine compound having benzyl(heterocyclicmethyl)amine structure and pharmaceutical product containing the same | KOWA CO | 2010-03-24 | — | — | CN | disclosed |
| US-7659271-B2 | Pyrimidine compound having dibenzylamine structure and medicament comprising the same | KOWA COMPANY, LTD. (JP) | 2010-02-09 | — | — | US | disclosed |
| EP-2149563-A1 | NOVEL PYRIMIDINE COMPOUND HAVING DIBENZYLAMINE STRUCTURE, AND MEDICINE COMPRISING THE COMPOUND | Kowa Company. Ltd. (JP) | 2010-02-03 | — | — | EP | disclosed |
| EP-2138489-A1 | NOVEL PYRIMIDINE COMPOUND HAVING BENZYL(HETEROCYCLICMETHYL)AMINE STRUCTURE AND PHARMACEUTICAL PRODUCT CONTAINING THE SAME | Kowa Company. Ltd. (JP) | 2009-12-30 | — | — | EP | disclosed |
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | KOWA COMPANY, LTD. (JP) | 2009-03-26 | — | — | US | disclosed |
| US-20090062306-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | KOWA COMPANY, LTD. (JP) | 2009-03-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090082352-A1 | N-{1-[3,5-bis(trifluoromethyl)phenyl]ethyl}-N-({2-[(cyclopentylmethyl)(ethyl)amino]-5-(trifluoromethyl)phenyl}methyl)-5-[2-(methylthio)ethoxy]pyrimidin-2-amine; inhibitory activity on cholesterol ester transfer protein (CETP) | CETP, NPC1L1, MTTP | CES2 88/4885RXRA 2791/4885RXRG 2346/4885 |
| US-20100249148-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | CETP, MTTP, NPC1L1 | CES2 156/4885RXRA 961/4885RXRG 1016/4885 |
| US-20090062306-A1 | NOVEL PYRIMIDINE COMPOUNDS HAVING BENZYL (HETEROCYCLIC METHYL) AMINE STRUCTURE AND MEDICAMENT COMPRISING THE SAME | CETP, MTTP, NPC1L1 | CES2 156/4885RXRA 961/4885RXRG 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.